“How I Knew I Had Ovarian Cancer”: A Patient’s Story Reveals an Unexpected Benefit of Daily Exercise
A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...
Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...
New magnetic nanoparticles in the shape of a cube sandwiched between two pyramids represent a breakthrough for treating ...
Oregon State University scientists have developed a highly efficient, uniquely shaped magnetic nanoparticle that could enable ...
Nemvaleukin alfa with pembrolizumab missed the overall survival primary end point in ARTISTRY-7 for platinum-resistant ...
New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...
Nemvaleukin alfa is an investigational engineered fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.
One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in ...
The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback